Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology
ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET were presented at the American College of Cardiology’s 69 th Scientific
Toggle Summary Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET will be presented at the American College of Cardiology’s 69 th Scientific
Toggle Summary Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors
ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Lipid Management team and our directors, I am very pleased to welcome
Toggle Summary Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 26, 2020, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 10,900 shares of its common stock and 59,291 restricted
Toggle Summary Esperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that the company will participate in fireside chats at the following conferences: Cowen 40th Annual Health Care Conference in Boston Monday, March 2, 2020 11:20 AM EST   Barclays Global Healthcare